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Abstract
Objective. The symptoms and long-term sequelae of SARS-
CoV-2 infection have yet to be determined, and evaluating
possible early signs is critical to determine which patients
should be tested and treated. The objective of this ongoing
study is to evaluate initial and short-term rhinologic symp-
toms, olfactory ability, and general quality of life in patients
undergoing SARS-CoV-2 testing.
Study Design. Prospective case-control.
Setting. Academic institute.
Methods. Adult patients tested for SARS-CoV-2 were prospec-
tively enrolled and separated into positive and negative groups.
Each participant completed 4 validated patient-reported
outcome measures. The UPSIT (University of Pennsylvania
Smell Identification Test) was distributed to patients who
were SARS-CoV-2 positive.
Results. The positive group reported significantly decreased
sense of smell and taste on the 22-item Sinonasal Outcome
Test (SNOT-22) as compared with the negative group (mean
6 SD: 3.4 6 1.7 vs 1.2 6 1.4, P \ .001). The positive group
had a much higher probability of reporting a decrease in
smell/taste as ‘‘severe’’ or ‘‘as bad as it can be’’ (63.3% vs
5.8%) with an odds ratio of 27.6 (95% CI, 5.9-128.8). There
were no differences between groups for overall SNOT-22
domain scores, PHQ-4 depression/anxiety (Patient Health
Questionnaire24), and 5-Level EQ-5D quality-of-life scores.
Mean Self-MOQ (Self-reported Mini Olfactory Questionnaire)
scores were 7.0 6 5.6 for the positive group and 1.8 6 4.0
for the negative group (P \ .001). The mean UPSIT score
was 28.8 6 7.2 in the positive group.
Conclusion. Symptomatic patients who are SARS-CoV-2 posi-
tive report severe olfactory and gustatory dysfunction via
the Self-MOQ and SNOT-22 as compared with symptomatic
patients testing negative.
Keywords
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T
he novel coronavirus disease 2019 (COVID-19) has
spread exponentially throughout the world causing a
significant threat to the health of the global popula-
tion. High viral loads of the causative severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) are harbored in
the upper respiratory tract, and the primary mode of trans-
mission is thought to occur through the spread of respiratory
droplets.1,2 Up to 56% of patients remain asymptomatic or
have very minor symptoms similar to common upper respira-
tory illnesses, including anosmia and nasal congestion.3
Several articles recently revealed that .50% of patients
with COVID-19 have smell and taste impairment.4-20 In
patients reported to have chemosensory dysfunction, 73.0%
noted anosmia prior to diagnosis, and it was the initial
symptom in 26.6%.4 A study in Iran utilizing objective vali-
dated testing found that 98% of inpatients with COVID-19
exhibited smell dysfunction.5 A recent systematic review of
10 studies reported a 52.7% and 43.9% prevalence of
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olfactory and gustatory dysfunction, respectively.6 However,
most studies utilized self-reported surveys and did not have
a control group for comparison. Nonetheless, the growing
evidence has led the US Centers for Disease Control and
Prevention and the World Health Organization to add loss
of smell and taste to the list of common symptoms that may
appear 2 to 14 days after viral exposure.
Though smell and taste dysfunction are now recognized
presentations of COVID-19, the onset, duration, and possi-
ble long-term consequences remain unknown. It is critical
to characterize the early signs of infection to determine
which patients should be tested, quarantined, and potentially
treated. Additionally, there is still much unknown about the
effect that the virus has on the mental well-being of patients
and on overall quality of life. The purpose of this prospec-
tive case-control study is to evaluate rhinologic symptoms,
self-reported and objective olfactory ability, anxiety and
depression, and health-related quality of life in symptomatic
patients undergoing SARS-CoV-2 testing.
Materials and Methods
This study was approved by the Indiana University institu-
tional review board. Patients who obtained a nasopharyngeal
swab for SARS-CoV-2 and underwent molecular testing for
symptoms concerning for COVID-19 (ie, fever, fatigue,
cough, shortness of breath pharyngitis, nasal congestion) at
Indiana University Health facilities across 9 Indiana coun-
ties were identified. Each patient’s electronic health record
was reviewed for contact information and demographic
data, which included age, race, gender, and medical history.
The following patients were excluded from the study: (1)
\18 years of age; (2) non-English speaking; (3) diagnosed
with a chronic debilitating medical condition that would
preclude participation, such as dementia; (4) admitted to an
intensive care unit or unstable at the time of chart review; (5)
no documented phone number or email address; and (6) neg-
ative test result for SARS-CoV-2 and no viral symptoms.
Patients who met the inclusion criteria were recruited by
phone call or email. If recruited by phone, email addresses
were obtained from each participant. Consent, HIPAA au-
thorization (Health Insurance Portability and Accountability
Act), and patient-reported outcome measures were comple-
ted in REDCap, a secure and HIPAA-compliant web appli-
cation for building and managing online surveys. Patients
were separated into positive and negative groups based on
the results of their SARS-CoV-2 testing. For patients who
tested negative, it was confirmed that they reported symp-
toms concerning for COVID-19 at the time of testing.
After consenting, participants rated their senses of smell at
baseline and while sick (0, no sense of smell; 10, normal
sense of smell). They then completed 4 validated surveys
electronically.
The Sinonasal Outcomes Test (SNOT-22) comprises 22
symptoms, each scored by severity (0, no problem; 5, as
bad as it can be), with scores ranging from 0 to 110.21
There are also 5 subdomain scores. The Self-reported Mini
Olfactory Questionnaire (Self-MOQ) consists of 14 true-false
items about olfactory problems in daily life, with scores rang-
ing from 0 to 14.22 The Patient Health Questionnaire 4
(PHQ-4) asks about 4 core depression and anxiety symptoms,
each scored 0 (not at all) to 3 (nearly every days), with the
total ranging from 0 to 12.23 The 5-Level EQ-5D (EQ-5D-
5L) has patients rate overall health status (0, worst health you
can imagine; 100, best health you can imagine) plus 5 dimen-
sions: mobility, self-care, usual activities, pain, and anxiety/
depression (0, no problem; 4, extreme problem).24 The over-
all health status score and the mean scores from the 5
dimensions were reported. Patients with smell or taste dys-
function were mailed the University of Pennsylvania Smell
Identification Test (UPSIT), and the results were collected
through email or mail. If patients were enrolled during an
active hospitalization, the test was delivered to the hospital
room. Data analysis was performed with Microsoft Excel
version 2004 and included the Student’s t test and the
Pearson correlation coefficient. Simultaneous 95% CI for
multinomial proportions were constructed in SAS version
9.4 (SAS Institute Inc) via the Goodman method.
Results
Surveys were completed by 49 patients who tested positive
for SARS-CoV-2 and by 34 who tested negative between
April 12 and May 4, 2020. Outpatients represented 87.8%
of the positive group and 97.1% of the negative group.
Demographics for each group are summarized in Table 1.
There were no significant differences between positive and
negative groups in age (P = .27), gender (P = .46), and race
(P = .50). Surveys were completed at a mean 6 SD 7.9 6
3.4 days after testing for the positive group and 8.4 6 4.4
days for the negative group (P = .57).
Patients rated their subjective senses of smell on a scale
of 0 to 10 at baseline and while exhibiting symptoms con-
cerning for COVID-19. There was no difference in baseline
sense of smell between the positive and negative groups
(9.1 6 2.1 vs 9.2 6 2.1, P = .87), but the positive group
had a highly significant lower mean sense of smell while
Table 1. Demographics of Survey Respondents.
SARS-CoV-2
Positive Negative P value
Total, No. 49 34











symptomatic as compared with the negative group (2.6 6
3.7 vs 7.1 6 2.7, P \ .001). The positive group also
reported significantly higher scores for decreased sense of
smell/taste on the SNOT-22 (3.4 6 1.7 vs 1.2 6 1.4, P \
.001; Table 2). The positive group had a much higher prob-
ability of reporting its decrease in smell/taste as ‘‘severe’’
or ‘‘as bad as it can be’’ (63.3% vs 5.8%) with an odds ratio
of 27.6 (95% CI, 5.9-128.8). There were no significant dif-
ferences between male and female scores for decreased
sense of smell/taste on the SNOT-22 for the positive group
(3.6 6 1.4 vs 3.3 6 1.8, P = .43) or the negative group (1.1
6 1.7 vs 1.3 6 1.4, P = .86). In addition, no differences
were noted between the groups in overall SNOT-22 scores
or the 5 symptom domains (Table 3). Mean Self-MOQ
scores were 7.0 6 5.6 for the positive group and 1.8 6 4.0
for the negative group (P \ .001). Based on Self-MOQ
scores, 6.1% of the positive group was considered hyposmic
(Self-MOQ score .3.5) and 55.1% anosmic (.4.5), while
no patients in the negative group were hyposmic and 14.7%
were anosmic. There were no significant differences
between male and female Self-MOQ scores for the positive
group (8.4 6 5.6 vs 6.3 6 5.5, P = .22) or the negative
group (1.9 6 4.1 vs 1.9 6 4.1, P = .99).
Eighteen individuals from the positive group completed
the UPSIT, with a mean score of 28.8 6 7.2 out of 40 pos-
sible total points. Hyposmia (UPSIT score, 20-31) was iden-
tified in 44.4% and anosmia (8-19) in 11.1%. Bivariate
analysis with Pearson correlation of the UPSIT and Self-
MOQ scores demonstrated a medium-strength negative
linear relationship (r = 20.45). This relationship is negative,
as a lower score on the UPSIT and a higher score on the
Self-MOQ indicate hyposmia/anosmia.
Mean PHQ-4 scores were 3.3 6 3.1 for the positive
group and 3.2 6 3.1 for the negative group (P = .92). The
positive group rated overall health status as 67.3 6 19.6, as
compared with 67.1 6 23.2 for the negative group (P =
.97). For the positive and negative groups, responses to
additional EQ-5D-5L questions averaged 0.3 6 0.7 vs 0.5
6 0.8 for mobility (P = .24), 0.2 6 0.5 vs 0.2 6 0.5 for
self-care (P = .85), 1.1 6 1.0 vs 0.8 6 1.0 for usual activi-
ties (P = .231), 1.0 6 0.9 vs 1.4 6 1.0 for pain/discomfort
(P = .09), and 0.8 60.9 vs 0.9 6 0.9 for anxiety/depression
(P = .60), respectively.
Discussion
As more data have been published on COVID-19, anosmia
continues to prove a common and early symptom displayed
by patients who contract the disease.6,7 Loss of smell and
taste has been found to strongly correlate with positive
SARS-CoV-2 testing in ambulatory patients presenting with
influenza-like symptoms.13-17 Two studies have also reported
a correlation between internet searches for smell-related
information and the incidence of SARS-CoV-2 infection,
showing that patients recognize anosmia as a symptom and
that its attention in the media is increasing public knowl-
edge on the condition.12,13 Strikingly, a recent meta-analysis
by Tong showed that 52.7% of patients with COVID-19
demonstrated olfactory dysfunction, and additional studies
have shown that up to 86% of outpatients who tested posi-
tive for SARS-CoV-2 have self-reported olfactory dysfunc-
tion.6,14,15,19 All of these findings underscore the need for
physicians to remain vigilant when dealing with patients
who present with viral illnesses and/or anosmia and for
there to be standardized methods to evaluate these patients
to determine if they need testing.
This prospective case-control study utilized cohorts of
patients who tested positive and negative for SARS-CoV-2
and evaluated them via questionnaires on subjective smell
ability, the SNOT-22, the Self-MOQ, the PHQ-4, and the
EQ-5D-5L in an attempt to better understand the ways in
which the virus can affect patients and to set up a method in
which symptoms can be tracked over time. Our results
demonstrate that during the symptomatic phase of the ill-
ness, patients with SARS-CoV-2 had a significantly dimin-
ished subjective sense of smell as compared with patients
testing negative. This correlated with the findings from the
validated patient-reported outcome measures, as the positive
cohort reported higher scores for decreased sense of smell
and taste on the SNOT-22 and the Self-MOQ.
This certainly seems to verify previously published data
that patients with COVID-19 have a similar viral prodrome
when compared with other common viruses but with smell
Table 2. SNOT-22 Responses for Severity of Decreased Sense of
Smell and Taste.
SARS-CoV-2 prevalence, % (95% CI)
Positive Negative
None 10.2 (3.4-26.9) 47.1 (27.0-68.1)
Very mild 6.1 (1.5-21.6) 14.7 (4.9-36.5)
Mild or slight 12.2 (4.5-29.4) 17.6 (6.5-39.8)
Moderate 8.2 (2.4-24.3) 14.7 (4.9-36.5)
Severe 30.6 (16.6-49.5) 2.9 (0.3-21.5)
As bad as it can be 32.7 (18.1-51.5) 2.9 (0.3-21.5)
Abbreviation: SNOT-22, 22-item Sinonasal Outcome Test.
Table 3. SNOT-22 Scores for Positive and Negative Cases of
SARS-CoV-2.
Score, mean 6 SD
SNOT-22 Positive Negative P value
Rhinologic 9.4 6 5.9 8.1 6 6.3 .34
Extranasal rhinologic 4.2 6 3.0 5.1 6 4.0 .26
Ear/facial 5.5 6 4.7 6.6 6 6.0 .38
Psychological 13.8 6 7.8 13.7 6 9.2 .93
Sleep dysfunction 10.8 6 7.1 11.1 6 7.3 .85
Total 36.7 6 18.9 37.2 6 24.4 .92
Abbreviation: SNOT-22, 22-item Sinonasal Outcome Test.
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seemingly affected to a greater degree. Viruses that give
rise to the common cold are well known to cause postinfec-
tious olfactory loss. In fact, postviral anosmia accounts for
approximately 18% to 45% of cases of anosmia, and the
natural history of viral-associated olfactory loss generally
includes some degree of spontaneous recovery.8 In the years
following initial diagnosis, 40% to 60% of patients with
postviral olfactory loss will have a measurable spontaneous
improvement, with 46% of anosmic and 35% of hyposmic
populations exhibiting significant improvement.10,11 How-
ever, only 15% of those with anosmia and 25% of those
with hyposmia will eventually recover normal olfaction.10
Several studies have looked into this relationship between
COVID-19 and olfactory dysfunction as a predictor for clin-
ical outcomes of the disease. Yan et al found that anosmia
strongly and independently correlated with outpatient man-
agement, while intact sense of smell and taste correlated
with hospital admission.20 This relationship was contra-
dicted by Moein et al, who found that 58% of inpatients had
either anosmia (25%) or hyposmia (33%), and Vaira et al,
who found no significant correlation between the extent of
smell and taste loss and the severity of the illness.5,25
Contradictory findings like these underline the need for
additional prospective data to evaluate the natural history of
anosmia after SARS-CoV2 infection.
As more studies are performed, it is critical that steps be
taken to collect long-term data with the initial presentation of
these patients. In looking at time course, Klopfenstein et al
reported that anosmia begins approximately 4 days after expo-
sure and that the mean duration of anosmia was 9 days, with
98% of patients completely recovered within 28 days.26
Interestingly, Hopkins et al evaluated 382 patients with a posi-
tive COVID-19 diagnosis via survey and found that 80.1%
reported subjective improvement in loss of smell and that
recovery appeared to plateau after 3 weeks.11 However, these
studies did not use validated tools to measure these outcomes.
To evaluate symptoms at the time of diagnosis and at sched-
uled intervals in the future, we combined the SNOT-22 ques-
tionnaire with the Self-MOQ. In addition, the UPSIT was used
to objectively evaluate patients with a positive COVID-19 diag-
nosis and self-reported olfactory dysfunction. These tests pro-
vide information on subjective and objective olfactory ability
and can be repeated to track severity over time and evaluate
patients for anosmia/hyposmia recovery.
The validated SNOT-22 questionnaire is a widely adopted
instrument to evaluate chronic rhinosinusitis treatment out-
comes, and the associated questions can be subcategorized
into 5 distinct clinical domains.21,27 To our knowledge, our
study is the first to utilize the SNOT-22 questionnaire for
comparison of positive and negative cases of SARS-CoV-2 .
When we considered the SNOT-22 question regarding the
single symptom of decreased sense of smell and taste in our
study, there was again a significant difference between the
positive and negative groups. However, the overall SNOT-22
scores and rhinologic, extranasal rhinologic, ear/facial, psy-
chological, and sleep dysfunction domain scores between the
cohorts were not significantly different, suggesting that the
overall symptoms represented by each domain are no differ-
ent for patients with common viral symptoms who test either
positive or negative for SARS-CoV-2.
In an attempt to evaluate subjective olfactory dysfunction
with a validated survey tool, we used the Self-MOQ. This
simple and reliable questionnaire used for screening olfac-
tory dysfunction was developed to reduce the time and
expense involved with other tests of quantitative olfactory
dysfunction.22 We found that patients who were SARS-
CoV-2 positive had clinically significant diminished olfac-
tion as compared with the negative cohort. Unfortunately,
the prevalence of short-term olfactory loss caused by upper
respiratory illnesses has not been well studied. On the basis
of the Self-MOQ, we report a 61.2% prevalence of self-
reported olfactory loss (6.1% hyposmia, 55.1% anosmia) in
patients who were SARS-CoV-2, which is .4 times higher
relative to those who were negative. To our knowledge, our
study is the first to evaluate the differences in olfaction
between the positive and negative groups utilizing any vali-
dated questionnaire specific to olfactory dysfunction.
Similar to the Self-MOQ, the UPSIT revealed a 55.5%
overall prevalence of olfactory loss in patients who were
SARS-CoV-2 positive, but hyposmia instead predominated
at 44.4%. This suggests that patients with COVID-19 are
able to accurately self-report severe olfactory dysfunction,
but there may be some overestimation of the actual degree
of severity as compared with objective testing. In addition,
a Pearson correlation for the Self-MOQ and the UPSIT
demonstrated a nearly significant medium-strength negative
linear relationship (r = 20.45). The Self-MOQ could easily
be included when screening patients with a concern for
COVID-19 in a setting where the UPSIT is difficult to
obtain, as a result showing hyposmia or anosmia should raise
suspicion and potentially lead to further testing.
As the COVID-19 health crisis deepens, it is important to
evaluate how infection with the virus, quarantining, and
social distancing affect the mental health and general qual-
ity of life of patients. The PHQ-4 was used to evaluate for
anxiety and depression, and the EQ-5D-5L was used to
evaluate the general health dimensions of mobility, self-
care, usual activities, pain/discomfort, and anxiety/depres-
sion.24,28,29 Our results did not show a significant difference
between the cohorts with regard to anxiety, depression, or
general well-being. However, this is a preliminary report,
and continued follow-up is necessary to understand potential
long-term sequelae.
The strengths of this study include utilizing multiple vali-
dated patient-reported outcome measures, an objective
olfactory test, a well-matched control group of patients with
negative SARS-CoV-2 status. It also demonstrates the corre-
lation of the Self-MOQ, suggesting a role for this test in the
screening of patients. Several limitations to this study war-
rant discussion. Recall bias may influence patients answer-
ing the 2 subjective olfactory questions. In particular, the
use of self-reported olfactory dysfunction can be influenced
by extraneous factors, especially in those who report symp-
toms after being informed of positive or negative diagnosis.
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Furthermore, the study sample represented those with a pre-
dominantly ambulatory clinical course, and these data may
not be generalizable to patients ill enough to require pro-
longed hospitalization. The cross-sectional nature of these
data would be strengthened by longitudinal data. Finally,
our small sample of UPSITs from the positive cohort (n =
18) makes our objective findings regarding olfactory dys-
function preliminary.
Conclusion
Our data demonstrate a significant difference in self-
reported olfactory ability based on the Self-MOQ and no
difference in self-reported anxiety/depression scores or gen-
eral quality of life via the PHQ-4 and ED-5D-5L, respec-
tively. We believe our study to be the first to directly
evaluate positive and negative cohorts where each presented
with viral symptoms, utilizing the SNOT-22 and the Self-
MOQ. Further research must be done to understand long-
term sequela of the virus
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